Format

Send to

Choose Destination
See comment in PubMed Commons below
Science. 2013 Jan 18;339(6117):286-91. doi: 10.1126/science.1232227.

Neutralizing tumor-promoting chronic inflammation: a magic bullet?

Author information

1
Department of Cell and Developmental Biology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239-3098, USA. coussenl@ohsu.edu

Erratum in

  • Science. 2013 Mar 29;339(6127):1522.

Abstract

There have been substantial advances in cancer diagnostics and therapies in the past decade. Besides chemotherapeutic agents and radiation therapy, approaches now include targeting cancer cell-intrinsic mediators linked to genetic aberrations in cancer cells, in addition to cancer cell-extrinsic pathways, especially those regulating vascular programming of solid tumors. More recently, immunotherapeutics have entered the clinic largely on the basis of the recognition that several immune cell subsets, when chronically activated, foster tumor development. Here, we discuss clinical and experimental studies delineating protumorigenic roles for immune cell subsets that are players in cancer-associated inflammation. Some of these cells can be targeted to reprogram their function, leading to resolution, or at least neutralization, of cancer-promoting chronic inflammation, thereby facilitating cancer rejection.

PMID:
23329041
PMCID:
PMC3591506
DOI:
10.1126/science.1232227
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center